Squamous cell carcinoma of the thymus: a case report of rapid response to cyclophosphamide, doxorubicin, cisplatin, and prednisone.
A woman with unresectable squamous cell carcinoma of the thymus was treated with combination chemotherapy consisting of cyclophosphamide, adriamycin, cisplatin, and prednisone. Rapid tumor response and hyperuricemia occurred within 10 days after the first course of chemotherapy. Mediastinal irradiation was given after two courses of chemotherapy. Chemotherapy was continued until the total dose of adriamycin reached 450 mg/m2. The patient is alive and well in remission more than 111 weeks after therapy was begun and more than 63 weeks after treatment was discontinued. Further study of this chemotherapeutic regimen in squamous cell carcinoma of the thymus is needed. Monitoring of serum uric acid levels may be required.
D000584:Amiloride / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004338:Drug Combinations / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D013953:Thymus Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D014527:Uric Acid / Q000097:blood
D004338:Drug Combinations; D006852:Hydrochlorothiazide; D014527:Uric Acid; C010247:amiloride, hydrochlorothiazide drug combination; D000584:Amiloride; D004317:Doxorubicin; D003520:Cyclophosphamide; D003404:Creatinine; D002945:Cisplatin; D011241:Prednisone